GoAI
Get started
King International Investment Limited logo

King International Investment Limited

0928.HK

HKSEHealthcareMedical - Diagnostics & Research

Open in GoAI

Latest quote

HK$0.102

−HK$0.005 · -4.67%

Aug 24, 1:28 PM HKTData delayed

0928.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

King International Investment Limited operates as a holding company, with its core activities focused on the provision of healthcare products and related services. The firm's business interests are diversified, also encompassing money lending and the distribution of alcoholic beverages. Its geographical reach extends across both mainland China and Hong Kong. Established on March 12, 2001, the company maintains its headquarters in Hong Kong.

Industry
Medical - Diagnostics & Research
Sector
Healthcare
Headquarters
HK
CEO
Yueyingtan Leng
Listed since
Apr 29, 2002
Employees
13

Market position

Day range

Current HK$0.102

52-week range

Current HK$0.102

Open
HK$0.098
Previous close
HK$0.107
Volume
160K
0.06× average
Average volume
2.79M
Average daily volume
Market cap
188.74M HKD
Beta
0.49
Market reference 1
50-day average
HK$0.0813
+25.49% above average
200-day average
HK$0.0869
+17.40% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
102×
P/B (TTM)
0.8×
P/S (TTM)
1.32×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
17.71%
Operating margin
6.72%
Net margin
1.29%

Financial health

Debt / equity
0.03×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends46%-13%-72%-131%Gross margin, FY2021: 14.81%Gross margin, FY2022: 5.38%Gross margin, FY2023: 16.17%Gross margin, FY2024: 31.23%Gross margin, FY2025: 17.71%Operating margin, FY2021: -34.09%Operating margin, FY2022: -14.53%Operating margin, FY2023: 7.55%Operating margin, FY2024: -32.28%Operating margin, FY2025: 6.33%Net margin, FY2021: -37.10%Net margin, FY2022: -11.25%Net margin, FY2023: 6.77%Net margin, FY2024: -116.41%Net margin, FY2025: 1.29%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 14.81%. Gross margin FY2022 5.38%. Gross margin FY2023 16.17%. Gross margin FY2024 31.23%. Gross margin FY2025 17.71%. Operating margin FY2021 -34.09%. Operating margin FY2022 -14.53%. Operating margin FY2023 7.55%. Operating margin FY2024 -32.28%. Operating margin FY2025 6.33%. Net margin FY2021 -37.10%. Net margin FY2022 -11.25%. Net margin FY2023 6.77%. Net margin FY2024 -116.41%. Net margin FY2025 1.29%.

Income trends

Revenue

143.23M HKD+251.35%

Operating income

9.06M HKD+22.22M HKD

Net income

1.84M HKD+49.3M HKD
Income trends across reported periods261.79M HKD149.34M HKD36.89M HKD−75.57M HKDRevenue, FY2021: 92.87M HKDRevenue, FY2022: 223.85M HKDRevenue, FY2023: 233.68M HKDRevenue, FY2024: 40.77M HKDRevenue, FY2025: 143.23M HKDOperating income, FY2021: −31.66M HKDOperating income, FY2022: −32.52M HKDOperating income, FY2023: 17.63M HKDOperating income, FY2024: −13.16M HKDOperating income, FY2025: 9.06M HKDNet income, FY2021: −34.46M HKDNet income, FY2022: −25.19M HKDNet income, FY2023: 15.82M HKDNet income, FY2024: −47.45M HKDNet income, FY2025: 1.84M HKDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 92.87M HKD. Revenue FY2022 223.85M HKD. Revenue FY2023 233.68M HKD. Revenue FY2024 40.77M HKD. Revenue FY2025 143.23M HKD. Operating income FY2021 −31.66M HKD. Operating income FY2022 −32.52M HKD. Operating income FY2023 17.63M HKD. Operating income FY2024 −13.16M HKD. Operating income FY2025 9.06M HKD. Net income FY2021 −34.46M HKD. Net income FY2022 −25.19M HKD. Net income FY2023 15.82M HKD. Net income FY2024 −47.45M HKD. Net income FY2025 1.84M HKD.
Metric (HKD)FY2025FY2024FY2023FY2022FY2021
Revenue143.23M HKD40.77M HKD233.68M HKD223.85M HKD92.87M HKD
Cost of goods sold117.86M HKD28.03M HKD195.89M HKD211.8M HKD79.12M HKD
Gross profit25.37M HKD12.73M HKD37.79M HKD12.05M HKD13.75M HKD
Selling, general, and administrative16.31M HKD25.89M HKD20.16M HKD44.57M HKD45.42M HKD
Operating expenses16.31M HKD25.89M HKD20.16M HKD44.57M HKD45.42M HKD
Interest income——1K HKD10K HKD6K HKD
Interest expense3.02M HKD793K HKD200K HKD227K HKD23K HKD
Depreciation and amortization570K HKD3.16M HKD3.6M HKD4.05M HKD1.55M HKD
Operating income9.06M HKD−13.16M HKD17.63M HKD−32.52M HKD−31.66M HKD
Net income1.84M HKD−47.45M HKD15.82M HKD−25.19M HKD−34.46M HKD

Company facts updated Aug 24, 2026.

Earnings

Latest EPS result
-0

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly EPS actual values compared with estimates0.050.01-0.03-0.06Q1 '21Q3 '21Q1 '22Q4 '22Q3 '23Q1 '24Q2 '24Q4 '24
Q1 2021, reported Mar 31, 2021: actual -0.004, estimate —, surprise —, Comparison unavailable. Q3 2021, reported Sep 30, 2021: actual -0.004, estimate —, surprise —, Comparison unavailable. Q1 2022, reported Mar 31, 2022: actual -0.023, estimate —, surprise —, Comparison unavailable. Q4 2022, reported Nov 29, 2022: actual -0.001, estimate —, surprise —, Comparison unavailable. Q3 2023, reported Jul 1, 2023: actual -0.016, estimate —, surprise —, Comparison unavailable. Q1 2024, reported Jan 31, 2024: actual 0.001, estimate —, surprise —, Comparison unavailable. Q2 2024, reported Jun 29, 2024: actual 0.009, estimate —, surprise —, Comparison unavailable. Q4 2024, reported Nov 29, 2024: actual -0.001, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly Revenue actual values compared with estimates180.41M121.8M63.19M4.57MQ1 '21Q3 '21Q1 '22Q4 '22Q3 '23Q1 '24Q2 '24Q4 '24
Q1 2021, reported Mar 31, 2021: actual 10.3M HKD, estimate —, surprise —, Comparison unavailable. Q3 2021, reported Sep 30, 2021: actual 87.49M HKD, estimate —, surprise —, Comparison unavailable. Q1 2022, reported Mar 31, 2022: actual 5.38M HKD, estimate —, surprise —, Comparison unavailable. Q4 2022, reported Nov 29, 2022: actual 56.41M HKD, estimate —, surprise —, Comparison unavailable. Q3 2023, reported Jul 1, 2023: actual 167.45M HKD, estimate —, surprise —, Comparison unavailable. Q1 2024, reported Jan 31, 2024: actual 83.43M HKD, estimate —, surprise —, Comparison unavailable. Q2 2024, reported Jun 29, 2024: actual 150.25M HKD, estimate —, surprise —, Comparison unavailable. Q4 2024, reported Nov 29, 2024: actual 37.19M HKD, estimate —, surprise —, Comparison unavailable.

0928.HK peers

WuXi AppTec Co., Ltd. logo

2359.HK

WuXi AppTec Co., Ltd.

HK$197.8

-3.89%

Jiangsu Hengrui Pharmaceuticals Co.,Ltd logo

1276.HK

Jiangsu Hengrui Pharmaceuticals Co.,Ltd

HK$46.74

-3.03%

BeOne Medicines AG logo

6160.HK

BeOne Medicines AG

HK$222.4

-2.46%

WuXi Biologics (Cayman) Inc. logo

2269.HK

WuXi Biologics (Cayman) Inc.

HK$48.60

-4.71%

Hansoh Pharmaceutical Group Company Limited logo

3692.HK

Hansoh Pharmaceutical Group Company Limited

HK$31.22

-5.62%

Innovent Biologics, Inc. logo

1801.HK

Innovent Biologics, Inc.

HK$100.2

-2.15%

Continue in GoAI

Research 0928.HK

research.disclaimer